Sign In
Buy ANTX
$4.80
+0.120 (+2.56%)
At Close: Jul 20, 2026
3 Penny Stocks To Buy With Just $750
10:36am, Tuesday, 24'th Sep 2024
Anyone with any experience as an investor knows that while penny stocks can produce strong returns, they're also risky.
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why
11:30am, Monday, 19'th Aug 2024
AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.
Why Is AN2 Therapeutics (ANTX) Stock Down 35% Today?
08:28am, Friday, 09'th Aug 2024
AN2 Therapeutics (NASDAQ: ANTX ) stock is taking a beating on Friday after the company provided an update on its EBO-301 Phase 2/3 study. AN2 Therapeutics notes that information comes from the Phase
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c
Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround
10:36am, Tuesday, 21'st May 2024
AN2 Therapeutics (ANTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in r
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
04:01pm, Tuesday, 14'th May 2024
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
04:10pm, Thursday, 28'th Mar 2024
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
08:17pm, Monday, 11'th Mar 2024
NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors are advised
Levi & Korsinsky, LLP Investigates Possible Securities Fraud Violations by AN2 Therapeutics, Inc. (ANTX)
04:45pm, Tuesday, 05'th Mar 2024
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possible
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possible
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
10:30am, Sunday, 03'rd Mar 2024
NEW YORK , March 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors are advised
NEW YORK, NY / ACCESSWIRE / February 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possi
AN2 Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ANTX
01:30pm, Tuesday, 27'th Feb 2024
NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possi
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
10:00am, Saturday, 24'th Feb 2024
NEW YORK , Feb. 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors are advised to c
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
06:20pm, Thursday, 15'th Feb 2024
NEW YORK , Feb. 15, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors are advised
